¸ð½Ã´Â±Û ÇÁ·Î±×·¥ ÃÊ·ÏÁ¢¼ö »çÀüµî·Ï ¹ßÇ¥ÀÚ ¾È³» ¹ßÇ¥ÀÚ ¾È³» Çà»çÀå¾È³» ¼÷¹Ú¾È³» Ȩ

Æ÷½ºÅÍ À¯ÀÇ»çÇ×

9¿ù 25ÀÏ(¸ñ) ¿ÀÀü 9½Ã ÀÌÀü±îÁö Æ÷½ºÅ͸¦ ºÎÂøÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.
¿ÀÀü 9½ÃºÎÅÍ "ÃÖ¿ì¼ö Æ÷½ºÅÍ»ó" ½É»ç°¡ ½ÃÀ۵˴ϴÙ.

1. Å© ±â : 63.6cm(°¡·Î) X 93.6cm(¼¼·Î)
2. ¼³Ä¡¹æ¹ý : Final ÇÁ·Î±×·¥Áö¿¡ °ÔÀçµÈ ÃÖÁ¾ Æ÷½ºÅÍ ¹øÈ£¸¦ ¹Ýµå½Ã È®ÀÎÇÑ ÈÄ,
        ÇØ´ç Æ÷½ºÅÍ ÆdzÚÀÇ ÇÏ´Ü°ú »ó´ÜÀ» ¸ÂÃß¾î ºÎÂø ºÎÂøÀç·á´Â °³º°Áغñ
3. Àü½Ã±â°£ : 2008³â 9¿ù 25ÀÏ(¸ñ) ¿ÀÀü 9½Ã ~ 27ÀÏ(Åä) ¿ÀÀü 11½Ã

27ÀÏ(Åä) ¿ÀÀü 11½ÃºÎÅÍ Æ÷½ºÅÍ ÆdzÚÀÌ Ã¶¼ö µÇ¿À´Ï ¿ÀÀü 10½Ã~11½Ã »çÀÌ¿¡ Æ÷½ºÅ͸¦ Å»ÂøÇϽñ⠹ٶø´Ï´Ù.

Æ÷½ºÅÍ - Àüü   /    ¸ðüžÆÀÇÇР  /    »ý½Ä³»ºÐºñÇР  /    ºÎÀÎÁ¾¾çÇР  /    ÀϹݺÎÀΰúÇÐ

[ Æ÷½ºÅÍ - »ý½Ä³»ºÐºñÇÐ ]

Exhibition Hall B
¹øÈ£ ¼º¸í ¼Ò¼Ó Á¦¸ñ
RE1 À̼º±â °Ç¾çÀÇ´ë FoxP3+ Á¶Àý T ¼¼Æ÷¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¸é¿ª º¯¼ö
RE2 À̼º±â °Ç¾çÀÇ´ë Foxp3+ Á¶Àý T ¼¼Æ÷ÀÇ ¿ù°æ Á⵿ֱ¾È º¯È­
RE3 À̼º±â °Ç¾çÀÇ´ë ¿ù°æÁֱ⿡ µû¸¥ ÀÚ¿¬»ì¼¼Æ÷ È°¼ºÀÇ º¯È­
RE4 À̼º±â °Ç¾çÀÇ´ë ¹Ýº¹À¯»ê ȯÀÚÀÇ CD56+ ¼¼Æ÷ÀÇ Æ¯Â¡
RE5 Á¤¾ð¼® °Ç¾çÀÇ´ë 3T3-L1 Áö¹æ¼¼Æ÷¿¡¼­ RBP-4ÀÇ ¹ßÇö¿¡ ´ëÇÑ ¿¡½ºÆ®·Î°Õ ¼ö¿ëüÀÇ ¿ªÇÒ
RE6 ±è¿ëÁø ¼­¿ïÀÇ´ë Recombinant follicle stimulating hormone (r-FSH) only protocol versus luteinizing hormone (LH) added FSH protocol for ovarian stimulation in GnRH antagonist IVF-ET cycles in normal responders
RE7 ¹ÚÀº¾Æ ¿ï»êÀÇ´ë Expression profiles of FGF23 in spermatozoa compared to normal and abnormal semen
RE8 ±èÁ¤ÈÆ ¿ï»êÀÇ´ë Administration of oxytocin antagonist improves implantation rates in patients with repeated failure of IVF/ICSI treatment
RE9 ±è¾Æ¸® Æ÷õÁß¹®ÀÇ´ë Correlation between conventional endometrial thickness and three-dimensional volume in ovulation induction
RE10 ³ëÀç¼÷ ÇѾçÀÇ´ë Implication of Oxygen level on the regulation of follicle growth in cultured mice ovaries in vitro
RE11 ȲÁ¤Çý ÇѾçÀÇ´ë ü¿Ü¼öÁ¤ ¹× ¹è¾ÆÀ̽ļúÀ» ½ÃÇàÇÑ ºÒÀÓ È¯ÀÚÀÇ Æ¯¼º¿¡ °üÇÑ ¿¬±¸
RE12 ¹®¼ºÀº ÁÁÀº¹®È­º´¿ø Ç÷Áß E2 ³óµµ°¡ ü¿Ü¼öÁ¤¼úÀÇ ÀÓ½ÅÀ²¿¡ ¹ÌÄ¡´Â ³óµµ ÀÇÁ¸Àû È¿°ú
RE13 ±è¹Ì¶ó °üµ¿ÀÇ´ë Clinical analysis of the patients with premature ovarian failure: compliance of the treatment
RE14 Á¤¾ð¼® °Ç¾çÀÇ´ë Relation of high sensitivity C-Reactive protein with metabolic syndrome in healthy menopausal women.
RE15 ±èÈÆ ¼­¿ïÀÇ´ë Æó°æ ¿©¼º¿¡¼­ Ƽº¼·Ð Ä¡·á ÈÄ Ç÷û ÁöÁú º¯È­¿Í °ñ¹Ðµµ º¯È­ »çÀÌÀÇ ¿¬°ü¼º
RE16 ¼ÛÀ翬 °¡Å縯ÀÇ´ë Comparison of BMD changes according to kinds of GnRH agonist for postoperative hormone therapy of endometriosis.
RE17 ¹ÚÇöÁ¤ ¼º±Õ°üÀÇ´ë The effectiveness of low dose estrogen alone as add-back therapy in postoperative GnRH analogues(GnRHa) adjuvant treatment in endometriosis
RE18 ÀÌ°æÈÆ °¡ÃµÀÇ´ë Interleukin-2 receptor ¥â gene C627T polymorphism in Korean women with endometriosis: a case control study
RE19 Àü¿µÀº ¿¬¼¼ÀÇ´ë Efficacy of clinical conditions, biomarkers and disease stage as prognostic factors of reproductive outcome after surgical treatment for endometriosis
RE20 ÀÌ°æ¿í °í·ÁÀÇ´ë ½ÅüÁö¼ö ¹× üÁú·®Áö¼ö(BMI)¿Í Àڱ󻸷ÁõÀÇ ÁøÇ൵¿ÍÀÇ ¿¬°ü¼º
RE21 ¹èÁø¿µ °æºÏÀÇ´ë Clinical characteristics of Korean PCOS women
RE22 Àü±ÕÈ£ ¿ï»êÀÇ´ë The outcome of in vitro fertilization and embryo transfer according to body mass index of patients with polycystic ovary syndrome
RE23 ±èÇöÁø ÀÌÈ­ÀÇ´ë µ¿¾Æ½Ã¾Æ ±¹³» ÀÌÁÖ ¿©¼ºÀÇ ¿ù°æ°ú °ñ¹Ðµµ¿¡ °üÇÑ ¿¬±¸
RE24 ±èÀ±¼÷ ¼øõÇâÀÇ´ë Acute pyelonephritis associated with ureteral stone of the unilateral kidney and hematometrocolpos in double uterus